Neurones (XPAR:NRO) ROC %: 27.77% (As of Dec. 2025)


XPAR:NRO Neurones XPAR:NRO
96 GF Score
Price €35.10
GF Value €50.23
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Neurones ROC %?

Neurones XPAR:NRO -0.28% 96 ROC % is 27.77% as of Dec. 2025. GuruFocus rates XPAR:NRO with a GF Score™ of 96/100 and a GF Value™ of €50.23 (Significantly Undervalued). The stock has 3 warning signs investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Neurones's annualized return on capital (ROC %) for the quarter that ended in Dec. 2025 was 27.77%.

As of today (2026-06-25), Neurones's WACC % is 6.89%. Neurones's ROC % is 25.36% (calculated using TTM income statement data). Neurones generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Neurones  (XPAR:NRO) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Neurones's WACC % is 6.89%. Neurones's ROC % is 25.36% (calculated using TTM income statement data). Neurones generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Neurones ROC % Related Terms


Neurones ROC % Historical Data

* Premium members only.

The historical data trend for Neurones's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurones ROC % Chart

Neurones Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.31 31.01 27.81 27.13 27.13

Neurones Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.26 23.18 27.55 21.29 27.77
XPAR:NRO
96GF Score
Neurones XPAR:NRO
ROC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurones ROC % Calculation

Neurones's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=75.783 * ( 1 - 27.29% )/( (198.279 + 207.95)/ 2 )
=55.1018193/203.1145
=27.13 %

where

Invested Capital(A: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=725.691 - 200.921 - ( 326.491 - max(0, 252.655 - 588.114+326.491))
=198.279

Invested Capital(A: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=749.032 - 200.301 - ( 340.781 - max(0, 250.055 - 608.529+340.781))
=207.95

Neurones's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=84.708 * ( 1 - 25.65% )/( (245.674 + 207.95)/ 2 )
=62.980398/226.812
=27.77 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=717.701 - 183.328 - ( 288.699 - max(0, 248.464 - 574.64+288.699))
=245.674

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=749.032 - 200.301 - ( 340.781 - max(0, 250.055 - 608.529+340.781))
=207.95

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of 27.77% mean?
Neurones (XPAR:NRO) has a ROC % of 27.77% as of Dec. 2025. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Neurones and its competitors.
Is Neurones' ROC % too high?
Neurones' current ROC % is 27.77%. The Software industry median ROC % is 3.12. Neurones' value of 27.77% is 790.1% above this industry median. Overall, Neurones has a GF Score™ of 96/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Neurones' ROC % compare to IBM and ACN?
Neurones' ROC % of 27.77% can be compared against companies in the Software industry. The industry median ROC % is 3.12. Neurones' value of 27.77% is 790.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Software company?
The median ROC % among Software companies is 3.12, based on 2,828 companies in the industry. Companies in the top quartile (top 25%) have a ROC % significantly above this median, while those in the bottom quartile fall well below. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neurones's current ROC % of 27.77% is 790.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Neurones and its competitors. For the Software industry, the median ROC % is 3.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neurones's current ROC % is 27.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurones stock overvalued right now?
Based on GuruFocus' analysis, Neurones (XPAR:NRO) is currently considered Significantly Undervalued. The stock's GF Value™ is €50.23, compared to a current price of €35.10 — trading 30.1% below its estimated fair value. The current ROC % is 27.77% and 790.1% above the Software industry median of 3.12. Neurones' overall GF Score™ is 96/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Neurones (XPAR:NRO), the current ROC % is 27.77% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neurones (XPAR:NRO) Overvalued in 2026?

Based on GuruFocus' analysis, Neurones stock appears to be undervalued. The current stock price of €35.10 is trading 30.1% below its estimated GF Value™ of €50.23. GuruFocus considers Neurones to be Significantly Undervalued.

Key valuation signals for XPAR:NRO:

  • ROC %: 27.77%
  • GF Value™: €50.23 vs. price of €35.10 (30.1% below fair value)
  • GF Score™: 96/100 with 3 warning signs
  • Industry Position: 790.1% above the Software median

No single metric tells the full story. See the XPAR:NRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Neurones Business Description

Other Exchanges 0GX2:UKNE9:Germany
Address 205 Avenue Georges Clemenceau, Immeuble Le Clemenceau 1 Building, Nanterre, FRA, 92024
Neurones is active in Consulting and Digital Services, with activities including Digital Transformation, Overall Offer, Infrastructure Hub, Applications Hub, Consulting Division, Managed Services, and Service Centers. It also conducts IT development, pre-sales activities, management of fixed-price projects, technical assistance, infrastructure operations, and cybersecurity, and provides an internal platform for multi-LLM assistants, including Microsoft Copilot, ChatGPT, Gemini, Claude, and Mistral. Its segments are Infrastructure Services, Application Services, and Consulting. Infrastructure Services generates the majority of revenue and includes Cloud, Infrastructure Management, DevOps, Cybersecurity, User Support, IT Service Management, Information System Governance, and Automation.
96GF Score

Get the complete analysis for XPAR:NRO

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€35.10
Price
€50.23
GF Value